Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,348 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed Not applicable Interventional Results available

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

NCT04419857
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High-calorie formula
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 31, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Promoting Palliative Care for People With Heart Failure

NCT06933875
View directory record Official record
Conditions
Heart Failure, Palliative Care
Interventions
Clinical Decision Support Tool
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660
View directory record Official record
Conditions
Healthy
Interventions
ARV-471, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 31, 2026, 10:47 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT02849496
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Surgery, Active Monitoring
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

NCT03599063
View directory record Official record
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 31, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Non-invasive Venous Pressure Estimation

NCT07226479
View directory record Official record
Conditions
Cardiac Intensive Care
Interventions
CPMX2
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Terminated Phase 1Phase 2 Interventional

First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

NCT05348889
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
Interventions
1A46 Injection
Drug
Lead sponsor
Chimagen Biosciences, Ltd
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Louisville, Kentucky • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 31, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

NCT03713320
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
Cobomarsen, Vorinostat
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

NCT02536196
View directory record Official record
Conditions
Symptomatic Aortic Stenosis
Interventions
Embolic Protection Device, Transcatheter aortic valve implantation (TAVI)
Device · Procedure
Lead sponsor
Keystone Heart
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PeriOperative ISchemic Evaluation-3 Trial

NCT03505723
View directory record Official record
Conditions
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions
Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Drug · Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
9,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Weston, Florida • New York, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Lebrikizumab, Pirfenidone, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

NCT06541678
View directory record Official record
Conditions
Healthy
Interventions
Danuglipron, Cyclosporine, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 31, 2026, 10:47 AM EDT
Recruiting Phase 3 Interventional

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

NCT05929768
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
955
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

NCT04605991
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY900014, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
30
States / cities
Concord, California • Escondido, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

NCT02974374
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
PF-06835919, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT03785964
View directory record Official record
Conditions
Desmoid Tumor, Aggressive Fibromatosis
Interventions
Nirogacestat oral tablet, Placebo Oral Tablet
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT05096663
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
Dietary Supplement · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
350
States / cities
Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

NCT03490838
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
177Lu-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 31, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

NCT05279092
View directory record Official record
Conditions
Total Knee Replacement, Knee Arthroplasty
Interventions
Bupivacaine-Liposomal Bupivacaine, Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)

NCT00814099
View directory record Official record
Conditions
Respiratory Insufficiency, Respiratory Distress Syndrome, Newborn, Lung Diseases
Interventions
Team approach to sedation management, Usual approach to sedation management
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Weeks to 18 Years
Enrollment
2,449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 10:47 AM EDT